1. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data. Issue 5 (3rd September 2019) Authors: Takeuchi, Tsutomu; Yamanaka, Hisashi; Yamaoka, Kunihiro; Arai, Shoko; Toyoizumi, Shigeyuki; DeMasi, Ryan; Fukuma, Yuri; Hirose, Tomohiro; Sugiyama, Naonobu; Zwillich, Samuel H.; Tanaka, Yoshiya Journal: Modern rheumatology Issue: Volume 29:Issue 5(2019) Page Start: 756 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Issue 10093 (29th July 2017) Authors: Fleischmann, Roy; Mysler, Eduardo; Hall, Stephen; Kivitz, Alan J; Moots, Robert J; Luo, Zhen; DeMasi, Ryan; Soma, Koshika; Zhang, Richard; Takiya, Liza; Tatulych, Svitlana; Mojcik, Christopher; Krishnaswami, Sriram; Menon, Sujatha; Smolen, Josef S Journal: Lancet Issue: Volume 390:Issue 10093(2017) Page Start: 457 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. Issue 2 (26th July 2016) Authors: Fleischmann, Roy M; Huizinga, Tom W J; Kavanaugh, Arthur F; Wilkinson, Bethanie; Kwok, Kenneth; DeMasi, Ryan; van Vollenhoven, Ronald F Journal: RMD open Issue: Volume 2:Issue 2(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE. (26th August 2022) Authors: Mysler, Eduardo; Tanaka, Yoshiya; Kavanaugh, Arthur; Aletaha, Daniel; Taylor, Peter C; Song, In-Ho; Shaw, Tim; Song, Yanna; DeMasi, Ryan; Ali, Mira; Fleischmann, Roy Journal: Rheumatology Issue: Volume 62:Number 5(2023) Page Start: 1804 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Issue 7 (31st January 2017) Authors: Cohen, Stanley B; Tanaka, Yoshiya; Mariette, Xavier; Curtis, Jeffrey R; Lee, Eun Bong; Nash, Peter; Winthrop, Kevin L; Charles-Schoeman, Christina; Thirunavukkarasu, Krishan; DeMasi, Ryan; Geier, Jamie; Kwok, Kenneth; Wang, Lisy; Riese, Richard; Wollenhaupt, Jürgen Journal: Annals of the rheumatic diseases Issue: Volume 76:Issue 7(2017) Page Start: 1253 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. Issue 2 (1st October 2019) Authors: Strand, Vibeke; Mysler, Eduardo; Moots, Robert J; Wallenstein, Gene V; DeMasi, Ryan; Gruben, David; Soma, Koshika; Iikuni, Noriko; Smolen, Josef S; Fleischmann, Roy Journal: RMD open Issue: Volume 5:Issue 2(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis. Issue 9 (6th August 2019) Authors: Charles‐Schoeman, Christina; DeMasi, Ryan; Valdez, Hernan; Soma, Koshika; Hwang, Lie‐Ju; Boy, Mary G.; Biswas, Pinaki; McInnes, Iain B. Journal: Arthritis & rheumatology Issue: Volume 71:Issue 9(2019) Page Start: 1450 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis. Issue 4 (4th November 2020) Authors: Fleischmann, Roy M; Blanco, Ricardo; Hall, Stephen; Thomson, Glen T D; Van den Bosch, Filip E; Zerbini, Cristiano; Bessette, Louis; Enejosa, Jeffrey; Li, Yihan; Song, Yanna; DeMasi, Ryan; Song, In-Ho Journal: Annals of the rheumatic diseases Issue: Volume 80:Issue 4(2021) Page Start: 432 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6. Issue 1 (27th December 2018) Authors: van Vollenhoven, Ronald F.; Lee, Eun Bong; Fallon, Lara; Zwillich, Samuel H.; Wilkinson, Bethanie; Chapman, Douglass; DeMasi, Ryan; Keystone, Edward Journal: Arthritis care & research Issue: Volume 71:Issue 1(2019) Page Start: 71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗